News
Events
Archive
LumiraDx Reports First Quarter 2022 Results
Wednesday 11 May 2022
Bill Gates Ted Talk: We Can Make COVID-19 the Last Pandemic | Bill Gates | TED
Friday 29 April 2022
LumiraDx Reports Fourth Quarter and Full Year 2021 Results
Thursday 10 March 2022
LumiraDx Announces Pricing of $56.5 Million Convertible Notes Offering
Tuesday 1 March 2022
LumiraDx Receives UK MHRA Approval for SARS-CoV-2 RNA STAR Complete
Monday 21 February 2022
LumiraDx Lab Analysis Confirms its COVID-19 Antigen Test Detects the Omicron Variant
Friday 14 January 2022
LumiraDx CRP Test Achieves CE Marking
Tuesday 11 January 2022
LumiraDx has Commenced Shipments in Europe for its COVID-19 & Flu A/B MicrofluidicAntigen Test
LumiraDx COVID-19 & Flu A/B Rapid Antigen Test Achieves CE Marking
Thursday 23 December 2021
LumiraDx Fast Lab Solutions Partners with Audere for At-Home Self- Collection Solution for use with SARS-CoV-2 RNA STAR Complete
Wednesday 15 December 2021
FDA Reissues LumiraDx Fast Lab Solutions’ EUA for SARS CoV-2 RNA STAR Complete Molecular Reagents to Allow High Throughput and Asymptomatic Testing Solutions
Wednesday 1 December 2021
LumiraDx Monitoring of New and Emerging Variants of Concern and Detection of the Omicron Variant
Monday 29 November 2021
LumiraDx Reports Third Quarter 2021 Financial Results
Wednesday 10 November 2021
LumiraDx to Announce Third Quarter 2021 Financial Results and Host Quarterly Conference Call on November 10
Tuesday 2 November 2021
LumiraDx receives approval for its COVID-19 Antigen Test for use in India
Wednesday 20 October 2021
LumiraDx Announces FDA EUA Submission for its SARS-CoV-2 & Flu A/B Rapid Antigen Test
Friday 15 October 2021
LumiraDx to Become Publicly Traded following Successful Closing of Merger with CA Healthcare Acquisition Corp.
Tuesday 28 September 2021
Bill & Melinda Gates Foundation’s Goalkeepers report features LumiraDx’s work in the fight against COVID-19
Tuesday 21 September 2021
LumiraDx and CA Healthcare Acquisition Corp Revise Transaction Terms, Expanded Strategic Roadmap for Next-Generation Point-of-Care Diagnostics
Friday 20 August 2021
PLOS Medicine publishes systematic review and meta-analysis of more than 60 SARS- CoV-2 antigen tests: Ranks LumiraDx’s SARS-CoV-2 Ag Test as most sensitive and accurate
Wednesday 18 August 2021
LumiraDx Receives FDA Emergency Use Authorization for its COVID-19 Antibody Test, Now Allowing COVID-19 Antigen and Antibody Testing on a Single Point of Care Platform
Thursday 5 August 2021
LumiraDx at ECCMID 2021: Performance Data presented on the use of the LumiraDx Platform with LumiraDx SARS-CoV-2 Ag and Ab Test
Friday 9 July 2021
LumiraDx Achieves CE Mark for Its High Sensitivity, High Throughput COVID-19 Molecular Test, RNA STAR Complete
Friday 2 July 2021
LumiraDx High Sensitivity Point of Care Antigen Test Detects Against Leading Variants of Concern including Alpha, Beta, Gamma, and Delta
Thursday 24 June 2021
LumiraDx Announces Commercial Launch of its SARS-CoV-2 Ag Pool Test in CE Mark countries
Thursday 17 June 2021
Shionogi Announces Agreement of Joint Sales with LumiraDx Japan for Novel Coronavirus Antigen test agent and diagnostic instrument in Japan
Wednesday 21 April 2021
LumiraDx Receives Reissued FDA Emergency Use Authorization for Its High Sensitivity, Rapid COVID-19 Molecular Lab Test
Tuesday 13 April 2021
LumiraDx, a Next-Generation Point of Care Diagnostics Testing Company to List on Nasdaq via Merger with CA Healthcare Acquisition Corp
Wednesday 7 April 2021
500 new Diagnostics jobs in Scotland at expanded global research hub
Thursday 18 March 2021
LumiraDx Receives SARS-CoV-2 Antigen Test Authorization in Japan and Brazil; Italy Recommends Expansion of Microfluidic Antigen Testing
Thursday 21 January 2021
SKUP Reports Positive Evaluation of the LumiraDx SARS-CoV-2 Antigen Test in Symptomatic and Asymptomatic Patients
Wednesday 13 January 2021
LumiraDx Receives Authorization by Switzerland´s Federal Office of Public Health
Monday 21 December 2020
Global Partnership to Introduce a Connected, Point of Care Diagnostic Platform for COVID-19 Antigen Testing in Africa
Tuesday 10 November 2020
LumiraDx COVID-19 Antigen Test Achieves CE Mark
Monday 31 August 2020
LumiraDx Receives FDA Emergency Use Authorization for Point of Care COVID-19 Antigen Test
Thursday 20 August 2020
LumiraDx at NHS Innovation Expo wins Silver at the World Exhibition Stand Awards 2020
Wednesday 24 June 2020
Drive through Warfarin Clinic supported by LumiraDx
Tuesday 19 May 2020
LumiraDx and Chembio announce COVID-19 Strategic Partnership
Thursday 12 March 2020
MEDICA 2019 World Forum of Medicine
Wednesday 11 December 2019
LumiraDx OPTIMAL Study Now Published
Wednesday 4 December 2019
LumiraDx Launches first-of-its-kind smart Diagnostic platform
Thursday 29 August 2019